<DOC>
	<DOCNO>NCT03092453</DOCNO>
	<brief_summary>Single arm open label trial assess safety tolerability mDC3/8 Vaccine ( Primer Booster ) subject stage III stage IV melanoma follow treatment Pembrolizumab .</brief_summary>
	<brief_title>Dendritic Cell Vaccination Patients With Advanced Melamona</brief_title>
	<detailed_description>After consent screening , subject apheresis perform approximately day -7 follow cyclophosphamide 300mg/m^2 intravenously mouth day -4 -3 . On Day 1 subject receive parin vaccine dose ( mature DC 7.5-15 million/peptide ) follow two booster dos ( every 6 week ) mature DC 1-5 million/peptode . Re-staging occur 3rd DC vaccine along tumor biopsy second apheresis . Anti PD-1 therapy ( standard care ) commence 7-8 week subject ' last DC vaccine .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically confirm stage III stage IV M1a/M1b/M1c melanoma Male female patient age &gt; 18 year ECOG performance status 02 Required initial laboratory value ( perform within 14 day prior enrollment ) : WBC &gt; 3,000/mm3 Hg great equal 9.0 gm/dl Platelets &gt; 75,000/mm3 Serum Bilirubin &lt; 2.0 mg/dl Serum Creatinine &lt; 2.0 mg/dl Subjects reproductive potential must agree use medically accept birth control method trial least two month follow trial . Provide write informed consent . Prior treatment one line cytotoxic chemotherapy ; prior treatment one line cytotoxic chemotherapy permit . Prior treatment target therapy ( ipilimumab , antiPD1 , BRAF + MEK inhibitor combination ) permit . Active untreated CNS metastasis Active infection Prior malignancy ( except nonmelanoma skin cancer ) within 3 year Pregnant nursing ( lactate ) woman Concurrent treatment systemic corticosteroid ; local ( inhaled topical ) steroid permit Known allergy egg Prior history uveitis autoimmune inflammatory eye disease Known positivity hepatitis BsAg , hepatitis C antibody , HIV antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>